Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration

Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration

(2023) Ella H Leung et al.   Clinical Ophthalmology

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

(2022) Jeffrey S Heier et al.   LANCET

Patient satisfaction following a switch from treat-and-extend to observe-and-plan regimen in age-related macular degeneration

(2022) Tora Sund Morken et al.   BMJ Open Ophthalmology

Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration

(2022) Yoko Kitajima et al.   JAPANESE JOURNAL OF OPHTHALMOLOGY

Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration

(2022) Ryan B Rush et al.   Clinical Ophthalmology

Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR

(2020) Masahito Ohji et al.   ADVANCES IN THERAPY

THE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES

(2020) Jeffrey S. Heier et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients

(2019) Iori Wada et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration

(2017) Jessica Boyle et al.   Psychology Health & Medicine

Conversion to Aflibercept For Chronic Refractory Or Recurrent Neovascular Age-Related Macular Degeneration

(2013) Yoshihiro Yonekawa et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

(2013) Usha Chakravarthy et al.   LANCET

Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON

(2013) Soraya Rofagha et al.   OPHTHALMOLOGY

Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life

(2012) Katharina M. Droege et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration

(2012) Jeffrey S. Heier et al.   OPHTHALMOLOGY

A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular DegenerationClinical and Economic Impact

(2010) Omesh P. Gupta et al.   OPHTHALMOLOGY

A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study

(2009) Geeta A. Lalwani et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY